Recalling the Treatment and Prognosis of Upper Tract Urothelial Cancer (UTUC)

May 2, 2024 updated by: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Among urothelial cancers, upper urinary tract urothelial cancers, including renal pelvis and ureteral cancers have a higher incidence rate in Taiwan than Western countries. In particular, the proportion of female patients is similar to that of males. This situation is significantly different from that in foreign countries. The cause is currently uncertain.In the past, the arsenic contamination of groundwater made blackfoot disease become common and malignant in areas. Now, the number of kidney dialysis patients in Taiwan is increasing; and according to statistics, there is a significantly higher incidence of urothelial cancer among kidney dialysis patients. This may be caused by the use of traditional Chinese medicine or other unknown reasons.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

8000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Taipei, Taiwan
        • Tzu chi hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with upper urinary tract urothelial carcinoma

Description

Inclusion Criteria:

  • Case study of upper urinary tract urothelial cancer surgery

Exclusion Criteria:

  • Cases of surgery for non-upper urinary tract urothelial cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
It is a retrospective and questionnaire-based study.
Time Frame: Patients with urothelial carcinoma of the upper urinary tract from January 2008 to December 2019.
Patients with urothelial carcinoma of the upper urinary tract from January 2008 to December 2019.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2018

Primary Completion (Actual)

February 8, 2018

Study Completion (Actual)

September 5, 2022

Study Registration Dates

First Submitted

May 2, 2024

First Submitted That Met QC Criteria

May 2, 2024

First Posted (Actual)

May 6, 2024

Study Record Updates

Last Update Posted (Actual)

May 6, 2024

Last Update Submitted That Met QC Criteria

May 2, 2024

Last Verified

February 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 06-X34-105

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Uterine Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe